Applied XL partners with STAT to launch a new clinical trials monitoring platform powered by artificial intelligence

Francesco Marconi
2 min readJan 19, 2022

STAT Trials Pulse provides biotech and pharma professionals with the earliest signals about clinical development through machine learning and editorial algorithms.

NEW YORK, NY — Today, STAT, the nation’s must-read health, science, and medicine publication, and AI company Applied XL, announced the launch of STAT Trials Pulse, an artificial intelligence platform that uses machine learning and editorial-driven algorithms to help life sciences professionals identify and prioritize the most important updates happening in the clinical trials space. The platform was developed by Applied XL, a company that builds real-time information systems rooted in computational journalism principles, in collaboration with STAT’s biotech reporting team.

“Our mission at STAT has always been to provide readers with leading coverage on health, science, and medicine. Now, STAT is expanding beyond reporting. With STAT Trials Pulse, our organization has taken a huge step in providing industry professionals with the insights and knowledge they need to succeed. Today’s announcement is a game changer for how we use technology to acquire information,” said Rick Berke, Co-Founder & Executive Editor of STAT.

STAT Trials Pulse includes the following features:

  • Personalized user experience: the platform creates tailored feeds that monitor specific conditions, interventions, and organizations that matter most to you, categorized and ranked by proprietary data points.
  • Timelines and smart updates: STAT Trials Pulse uses these data points to build dynamic timelines for each clinical trial, notifying users of trial stops, delays, and completions. Smart updates alert users about trial changes as they happen and provide explanatory context.
  • Trends: the platform indicates trends based on clinical trial event outliers, allowing users to surface emerging new research activities, potential disruptions to clinical pipelines and regulatory roadblocks.

“We leveraged our proprietary event and trend detection systems to build a product that translates the best practices of computational journalism into a next generation business intelligence platform. There is a growing demand among pharma operators and biotech investors for tools that can help cut through information overload and enable faster decision-making. STAT Trials Pulse fulfills these needs, giving users an unbeatable competitive advantage by surfacing signals before they become news,” said Francesco Marconi, Co-Founder & CEO of Applied XL.

Additionally, a team of STAT journalists will be curating diverse and timely feeds relevant to researchers, scientists, and journalists. The team includes biotech senior writer Adam Feuerstein, medicine senior writer Matthew Herper, and general assignment reporter Kate Sheridan. STAT Trials Pulse is available for a 4-week free trial to all new users that sign up. The platform’s annual cost is $1500.

--

--